Today: 8 June 2026
Browse Category

NASDAQ:DWAV 5 January 2026 - 29 April 2026

Quantum Stocks With Growth Potential in April-May 2026: 4 Names Facing a May Reality Check

Quantum Stocks With Growth Potential in April-May 2026: 4 Names Facing a May Reality Check

IonQ, Rigetti, and D-Wave will report earnings between May 6 and May 12, with investors watching revenue, bookings, and cash burn. IonQ shares last traded at $43.08, Rigetti at $16.39, D-Wave at $18.11, and Quantum Computing Inc. at $8.57, all with negative price-to-earnings ratios. IonQ announced a quantum-safe network project in Florida. The sector faces pressure from new IPOs and SPACs.
29 April 2026
····
D-Wave Quantum stock slides after Quantum Circuits deal closes and a 10.4 million-share resale filing hits

D-Wave Quantum stock slides after Quantum Circuits deal closes and a 10.4 million-share resale filing hits

D-Wave Quantum shares fell 6.2% to $27.04 after registering 10.43 million shares for resale tied to its $532 million Quantum Circuits acquisition. The company will not receive proceeds from these sales. Trading volume reached about 51 million shares. Investors are watching for updates at D-Wave’s Qubits conference next week.
21 January 2026
···
D-Wave Quantum stock jumps 8% before the bell as CES 2026 puts quantum back on traders’ radar

D-Wave Quantum stock jumps 8% before the bell as CES 2026 puts quantum back on traders’ radar

D-Wave Quantum shares jumped 7.6% to $28.13 in premarket trading Monday as CES 2026 opened in Las Vegas. Peer quantum stocks IonQ, Rigetti, and Quantum Computing Inc also traded higher. D-Wave is set to showcase its quantum systems at the CES Foundry event Jan. 7-8. The company’s Qubits 2026 user conference is scheduled for Jan. 27-28 in Boca Raton, Florida.
5 January 2026
·····

Stock Market Today

  • Stock Market Update: Dow Expected to Weaken, Nasdaq to Gain After Sharp Dip; Oil Prices Surge Amid Middle East Conflict
    June 8, 2026, 9:06 AM EDT. The Dow Jones Industrial Average is set to weaken while the Nasdaq Composite is poised for gains after the S&P 500 experienced its worst day since October. This downturn follows renewed violence in the Middle East, with Iran striking Israel, escalating geopolitical tensions. Oil prices jumped significantly, reflecting concerns over supply disruptions linked to the conflict. Investors remain cautious as markets digest the impact of escalating regional instability on global economic outlooks.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Go toTop